
















170Increased minimum vein diameter on preoperative
mapping with duplex ultrasound is associated with
arteriovenous ﬁstula maturation and secondary
patency
Leigh Anne Dageforde, MD, MPH,a,b Kelly A. Harms, BA,a Irene D. Feurer, PhD,a,b,c and
David Shaffer, MD, FACS,a,b Nashville, Tenn
Objective: Autogenous arteriovenous hemodialysis accesses (arteriovenous ﬁstulas [AVFs]) are preferred for chronic he-
modialysis access. Preoperative vein mapping by duplex ultrasound is recommended before AVF creation, but there are
few data correlating vein diameter with postoperative outcomes. Also, vein diameter has not been included in prior
predictive models of ﬁstula maturation. This study aims to test whether preoperative vein diameter is associated with
failure of AVF maturation and long-term (secondary) patency.
Methods: We performed a retrospective analysis of clinical variables of patients undergoing brachiobasilic or brachioce-
phalic AVF creation. Kaplan-Meier and multivariate Cox regression models tested whether preoperative minimum vein
diameter (MVD) and clinical covariates were associated with failure of AVF maturation and secondary patency.
Results: The sample included 158 adults (54 6 14 years; 45% male; 61% white; 56% diabetes; body mass index, 32 6 8;
MVD, 3.4 6 1.1 mm; follow-up, 12 6 9 months [range, <1-40 months]). Increased MVD was associated with decreased
risk of AVF failure. More than one third of AVFs with MVD <2.7 mm failed to mature within 6 months. Multivariate
models that adjusted for age, diabetes, race, gender, body mass index, and preoperative dialysis status demonstrated that
increased MVD was associated with decreased risk of failure of maturation and better long-term patency overall (P [
.005 and P [ .001, respectively).
Conclusions: Patients with a larger MVD on preoperative vein mapping are at lower risk for failure of ﬁstula maturation
and have increased long-term AVF patency. MVD is the only clinical or demographic factor associated with both AVF
maturation and long-term patency. MVD is an important preoperative indicator of ﬁstula success in assessment of
potential AVF sites. Future predictive models of ﬁstula maturation and patency should include MVD. (J Vasc Surg
2015;61:170-6.)Autogenous arteriovenous hemodialysis accesses (arte-
riovenous ﬁstulas [AVFs]) are the preferred vascular access
for chronic hemodialysis because of higher patency rates,
reduced complications, and reduced costs compared with
prosthetic arteriovenous grafts or central venous cathe-
ters.1,2 Despite an increase in AVF use since establishment
of the original National Kidney Foundation Kidney Disease
Outcomes Quality Initiative (NKF-KDOQI) Clinical Prac-
tice Guidelines for Vascular Access and the subsequent Fis-
tula First Breakthrough Initiative beginning in 2005, few
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://dx.doi.org/10.1016/j.jvs.2014.06.092two thirds of patients using AVF for dialysis, and consider-
able variation in the prevalence of AVF use among different
networks remains.3-5
In addition to recommending the use of AVFs for dial-
ysis, the NKF-KDOQI, the Fistula First Breakthrough
Initiative, and the Society for Vascular Surgery promote
preoperative duplex ultrasound as the standard of care
before placement of an AVF.4-6 Preoperative duplex ultra-
sound is recommended before AVF creation,4-6 and previ-
ous studies suggest that its routine use can increase the
placement of an autogenous arteriovenous access and the
proportion of patients undergoing dialysis with an AVF.7,8
Despite the routine use of duplex ultrasound, the fail-
ure rate of AVFs remains high. Recent single-center studies
still report a primary AVF failure rate of 26% to 50% and a
primary 1-year patency rate of 36% to 46% for a primary
AVF.9-14 In the multicenter Dialysis Access Consortium
study, 60% of AVFs failed to mature.15 Moreover, there
are few data speciﬁcally correlating vein diameter with post-
operative outcomes. Although some experts suggest a vein
diameter of 2.5 mm as adequate for AVF creation, there are
few published data to validate this threshold or to correlate
initial vein diameter with subsequent AVF matura-
tion.7,16,17 One study that did include preoperative vein
diameter as a predictor of ﬁstula maturation was limited
to patients with ﬁrst-time dialysis access placement and
Table I. Cohort clinical and demographic characteristics
Variable Cohort (N ¼ 158)




BMI 32 6 8
CAD 46 (29)
PVD 13 (8)
Follow-up time, months 12 6 10
Range, months (follow-up time) <1-40
Brachiocephalic ﬁstula 104 (66)
Brachiobasilic ﬁstula 54 (34)
MVD, mm 3.4 6 1.1
Preoperative dialysis 99 (59)
Used for dialysis postoperatively 82 (53)
BMI, Body mass index; CAD, coronary artery disease;MVD, minimum vein
diameter; PVD, peripheral vascular disease; SD, standard deviation.
Continuous data are presented as mean 6 standard deviation and cate-
gorical data as number (%).
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the patients enrolled in the study underwent preoperative
vein mapping.10 The aim of this study was to test whether,
after adjustment for clinical factors, vein diameter as
measured by preoperative duplex ultrasound is associated
with AVF maturation or long-term (secondary) patency
in patients both with and without prior arteriovenous
access.
METHODS
After Institutional Review Board approval, we per-
formed a retrospective review of patients who underwent
new AVF access creation from February 2009 to June
2011 by one of three surgeons who perform all of the
vascular access operations at a single medical center. The
Institutional Review Board authorized waiver of consent.
The selection criteria for type of arteriovenous access fol-
lowed KDOQI and Society for Vascular Surgery guide-
lines3,6 (radiocephalic preferred ﬁrst, then brachiocephalic,
then brachiobasilic, then prosthetic graft), with the speciﬁc
procedure determined independently by the operating sur-
geon on the basis of the patient’s history, physical examina-
tion ﬁndings, and preoperative duplex ultrasound study.
The majority of ﬁstulas were placed under general anes-
thesia. Heparin was not administered at the time of arterial
clamping, and antiplatelet medications were usually
continued perioperatively. Surgeons did not repeat vein
measurements with ultrasound in the operating room. All
brachiobasilic ﬁstulas were superﬁcialized as a second-stage
procedure 4 to 6 weeks postoperatively.
Patients younger than 18 years, those without preoper-
ative vein mapping, and those using the ﬁstula for intermit-
tent plasmapheresis were excluded. Patients who underwent
placement of a radiocephalic ﬁstula were excluded because
forearm cephalic vein measurements were not uniformly
recorded in the results from the vascular laboratory. The
presence or absence of central venous stenosis was not uni-
versally assessed in all patients and thus was not included in
our model. Patients with a prior failed ﬁstula or graft or a
prior tunneled dialysis catheter but undergoing a new arte-
riovenous access were included in the study cohort. AVF re-
visions were not included.
Minimum vein diameter (MVD) was determined from
the results of preoperative duplex ultrasound performed
at our center in a single Intersocietal Accreditation
Commission-accredited vascular ultrasound laboratory by
the same four vascular ultrasound technicians throughout
the study period. Intraobserver and interobserver agreement
was not determined because the data were obtained retro-
spectively by chart review. Four measurements of maximum
axis of vein lumen diameter were made by the vascular ultra-
sound technicians: antecubital fossa, distal, midpoint, and
proximal. The duplex ultrasound examination was per-
formed without a tourniquet by a Philips iU22 ultrasound
machine (Philips, Bothell, Wash) with a high-frequency (5-
9 MHz) linear probe. Patients sat upright with arms
extended, resting supine on apillow.Veindiametermeasure-
mentswere recorded for both arms in themedical record andwere extracted for this project. Archived images were not
reviewed. Arterial size and quality were not standardly
assessed. The MVD was the measure used in our analysis in
anticipation that the narrowest portion of the vein would
provide the best indicator of potential decreased ﬂow, high
velocity, pre-existing stenosis, and overall risk for failure.
Baseline patient demographic data, clinical comorbid-
ities, and dialysis status were extracted from the patient’s
hospital electronic medical record and outpatient dialysis
records and are summarized in Table I. Coronary artery
disease (CAD) was deﬁned as a history of myocardial
infarction or prior coronary revascularization by either
stenting or bypass surgery. Peripheral vascular disease
(PVD) was deﬁned as a history of lower extremity revascu-
larization, digit or extremity amputation, or claudication or
ischemic extremity changes. Fistula maturation was deﬁned
as at least one successful use of the ﬁstula with two needles
for dialysis after a clinical determination by the operating
surgeon and dialysis technician that the AVF was ready to
be cannulated. Duplex ultrasound was not routinely used
to determine maturation or readiness for cannulation.
Long-term or secondary patency was deﬁned as the time
to ﬁstula abandonment and could include open or percuta-
neous interventions to maintain patency.
Analysis. Statistical analyses were performed with
SPSS Statistics V21 (IBM Corp, Armonk, NY). The fre-
quency distribution of MVD for the entire sample was
examined, and the 25th, 50th, and 75th percentile rank
values were used to statistically deﬁne MVD quartiles.
Each patient’s MVD was classiﬁed as being within the ﬁrst,
second, third, or fourth quartile. Univariate Kaplan-Meier
survival analysis with log-rank tests was used to determine
whether preoperative MVD quartile was associated with
AVF maturation and long-term patency.
Multivariate Cox regression models, in which MVD
was treated as a continuous variable (diameter in millime-
ters), tested whether the clinical covariates were associated
with AVF maturation or long-term patency. Delays in
Fig 1. A total of 158 patients with brachiocephalic or brachio-
basilic ﬁstulas were included in the study cohort.
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placement may have been due to a delay in the progression
to end-stage renal disease and not problems with AVF
maturation. We accounted for this by including preopera-
tive dialysis status (yes/no) in the multivariate Cox models.
Prior ﬁstula and tunneled dialysis catheter placement were
not included in the multivariate models because they were
closely associated with preoperative dialysis status and
would have been statistically redundant.
In the ﬁstula maturation models, the terminal event
was failure of the ﬁstula before use for dialysis. Time was
deﬁned as months from the ﬁstula operation to the use
of the ﬁstula for dialysis or when a censoring event
occurred. Censoring occurred when the ﬁstula (1) was
used for dialysis or (2) was functioning but had not been
used for dialysis at the time of loss to follow-up, death, kid-
ney transplantation, or ﬁstula ligation for steal. Death and
kidney transplantation were considered censored events if
the ﬁstula was functioning because the ﬁstulas could have
been used for dialysis had these events not occurred. Liga-
tion for steal was considered a censored event in the pri-
mary models because the ﬁstula could potentially have
been used for dialysis if there were no symptoms of steal
that necessitated ligation. However, a secondary analysis
with ligation deﬁned as a failure event was also performed.
In the long-term patency models, the terminal event
was ﬁstula failure before or after use for dialysis. Time
was deﬁned as months from the ﬁstula operation to ﬁstula
abandonment or when a censoring event occurred.
Censoring occurred if the ﬁstula (1) was functioning but
not in use or (2) was being used for dialysis and a censoring
event occurred, including loss to follow-up, death, kidney
transplantation, or ﬁstula ligation for steal. A secondary
model of long-term patency, which comprised the same co-
variate set and may be overﬁtted because of the reduced
sample size, included only those patients who reached
dialysis.
RESULTS
Between February 2009 and June 2011, 278 new arte-
riovenous accesses (194 AVFs [70%], 84 prosthetic arterio-
venous grafts [30%]) were placed by one of three surgeons
at a single medical center. Of the 194 patients who had an
AVF placed, 36 were excluded from further analysis for not
having vein mapping on chart review (n ¼ 17), having a
radiocephalic ﬁstula (n ¼ 14), being younger than 18 years
(n ¼ 1), or having a ﬁstula placed for plasmapheresis (n ¼
4), leaving a total of 158 patients in the study cohort
(Fig 1). Of these, 32 patients (20%) had the ﬁstula fail
before use because of either failure to mature (n ¼ 13)
or thrombosis (n ¼ 19). Other causes of nonuse for dialysis
included ligation for steal (n ¼ 8), death before use (n ¼
10), and transplantation before use (n ¼ 4). In 20 patients
(13%), the patient was not yet on dialysis at the time of loss
to follow-up. Consequently, 84 (53%) of patients’ ﬁstulas
were ultimately used for dialysis during the study period.
Clinical and demographic characteristics of the cohort
are summarized in Table I. There were 104 patients(66%) who had a brachiocephalic ﬁstula placed, and 54
(34%) had a brachiobasilic ﬁstula. The study population
was 45% male and 61% white, and 56% had diabetes. The
mean age was 54 6 14 years, and mean body mass
index (BMI) was 32 6 8. The mean total follow-up was
12 6 9 months, and the follow-up time ranged
from <1 month to 40 months (Table I). Thirty-one pa-
tients (20%) had a total of 43 prior arteriovenous access
procedures (19 patients had one, nine patients had two,
and three patients had three prior arteriovenous accesses),
including 24 ﬁstulas (12 radiocephalic, nine brachioce-
phalic, and three brachiobasilic) and 19 prosthetic grafts.
Thirteen patients (8% of the total cohort, 42% of those
with a prior arteriovenous access) had a prior access on
the same side as the new AVF. Seventy-eight patients
(49%) had a prior tunneled dialysis catheter, 25 (16%) of
whom had the prior catheter on the same side as the
AVF. During the study period, there were a total of 31 sub-
sequent procedures to facilitate ﬁstula maturation (six an-
gioplasty alone, eight ligation of collaterals, 17 other
surgical) and 85 subsequent procedures to maintain access
patency (four angioplasty plus stent, 56 angioplasty alone,
four ligation of collaterals, 17 other surgical).
Vein diameter data were normally distributed with a
mean of 3.4 6 1.1 mm. MVD quartiles were deﬁned for
this cohort as follows: quartile 1, <2.7 mm; quartile 2,
2.7 to 3.2 mm; quartile 3, 3.3 to 4.1 mm; and quartile
4, >4.1 mm (Fig 2). Kaplan-Meier analysis indicated that
increased MVD was associated with decreased risk of
Fig 2. Histogram demonstrating the normal distribution of the
minimum vein diameter (MVD) in this cohort and the four
quartiles (Q1-Q4) that were used in the univariate Kaplan-Meier
models of ﬁstula maturation and overall ﬁstula survival.
Q1, <2.7 mm; Q2, 2.7 to 3.2 mm; Q3, 3.3 to 4.1 mm; Q4,
>4.1 mm.
Fig 3. Kaplan-Meier curve of ﬁstula maturation. Patients with
minimum vein diameter (MVD) in quartile 3 (Q3) or quartile 4
(Q4) had statistically signiﬁcantly increased likelihood of ﬁstula
maturation compared with patients in quartile 1 (Q1;
MVD <2.7 mm). Six-month survival estimates (standard error
[SE]) for quartiles 1 through 4, respectively, were .63 (.12), .79
(.08), .89 (.05), and .90 (.06). Twelve-month estimates were .54
(.13), .61 (.13), .73 (.12), and .70 (.11). Eighteen-month esti-
mates were .54 (.13), .61 (.13), .73 (.12), and .70 (.11).
JOURNAL OF VASCULAR SURGERY
Volume 61, Number 1 Dageforde et al 173failure to mature, which is synonymous with an increased
likelihood of ﬁstula maturation (Fig 3). Fistulas with a
vein diameter in the upper two quartiles (MVD
$3.3 mm) had signiﬁcantly greater likelihood of ﬁstula
maturation than did ﬁstulas in the lowest quartile
(MVD <2.7 mm). More than one third of AVFs with
MVD <2.7 mm failed to mature by 6 months. Similarly,
in the model of long-term patency, the ﬁstulas in the upper
two quartiles (MVD $ 3.3 mm) had a signiﬁcantly higher
likelihood of long-term survival compared with the ﬁstulas
in the lowest quartile (MVD <2.7 mm) (Fig 4). AVFs with
MVD <2.7 mm were associated with a higher risk of failure
of maturation and a lower long-term patency than were
AVFs with MVD $3.3 mm (Table II). To verify our pre-
diction that MVD would be the vein measurement best
associated with ﬁstula failure, we did test maximum vein
diameter and it was not strongly associated with ﬁstula
failure.
Multivariate Cox regression models were used to
analyze associations of demographic and clinical covariates
as well as MVD with ﬁstula maturation and long-term ﬁs-
tula patency. After controlling for age, diabetes, race, sex,
CAD, PVD, and preoperative dialysis status, increased
vein diameter was associated with an increased likelihood
of maturation and better overall patency (Tables III and
IV). Speciﬁcally, the hazard ratios (HRs) indicate that for
each 1.0-mm increase in MVD, there was approximately
a 45% reduction in the risk for failure of maturation (HR,0.555; P ¼ .005) and a 36% reduction in the risk of ﬁstula
failure (HR, 0.639; P ¼ .001). Age, sex, race, preoperative
dialysis status, and BMI were not statistically signiﬁcant in
any of the multivariate models. Having CAD was signiﬁ-
cantly associated with a decreased overall risk of ﬁstula fail-
ure (P ¼ .039), and preoperative dialysis was associated
with increased risk of ﬁstula failure (P ¼ .022)
(Table IV). The secondary analyses, in which ﬁstula liga-
tion was considered a failure instead of a censoring event,
were completely consistent with the primary analyses, and
increased MVD was associated with decreased failure of
maturation (HR, 0.609; P ¼ .007) and increased second-
ary patency (HR, 0.660; P ¼ .002). In the additional
multivariate model, which included the same covariates
and was limited to the 84 patients whose ﬁstula was used
for dialysis, increased MVD persisted as the only variable
associated with long-term patency (HR, 0.642; P ¼ .045).
DISCUSSION
Our data demonstrate, by use of univariate and multi-
variate statistical methods, that increased preoperative vein
diameter (MVD) is associated with an increased likelihood
of ﬁstula maturation and better long-term ﬁstula patency.
Conversely, as the vein diameter decreases, there is an
increased risk of the failure of maturation and a signiﬁcant
reduction in overall long-term AVF patency. Vein diameter
Fig 4. Kaplan-Meier curve of long-term ﬁstula survival. Patients
with minimum vein diameter (MVD) in quartile 3 (Q3) or quartile
4 (Q4) had a statistically signiﬁcantly increased likelihood of
ﬁstula survival compared with patients in quartile 1 (Q1;
MVD <2.7 mm). Six-month survival estimates (standard error
[SE]) for quartiles 1 through 4, respectively, were .67 (.08), .77
(.08), .90 (.05), and .91 (.05). Twelve-month estimates were .63
(.08), .55 (.10), .67 (.08), and .78 (.07). Eighteen-month esti-
mates were .42 (.10), .49 (.10), .63 (.08), and .78 (.07). Twenty-
four-month estimates were .29 (.10), .49 (.10), .58 (.09), and .71
(.10). Thirty-month estimates were identical to the 24-month
estimates.
Table II. Kaplan-Meier estimates of ﬁstula maturation

















6 months 63 79 90 90
Long-term
patency
6 months 67 77 90 91
12 months 63 55 67 78
24 months 29 49 58 71
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both AVF maturation and long-term patency in our study.
Our study is similar to earlier studies7,10,18 reporting
that vein diameter measured by preoperative duplex ultra-
sound is associated with ﬁstula outcomes.7,10,18 Whereas
other studies have reported vein diameter to be statistically
signiﬁcant, most use mean or maximum vein diameter in
analyses.10 We chose to use the MVD measurement
because MVD accounts for the smallest possible vein size
that might occur when a patient is vasoconstricted at the
time of duplex ultrasound examination. Despite potential
vasoconstriction, vein diameter on duplex ultrasound ex-
amination has been found to be accurate compared with
intraoperative ﬁndings of vein diameter.7
This study is also unique because the cohort included
patients with prior tunneled dialysis catheters and prior
arteriovenous access procedures as well as patients under-
going initial placement of an AVF. Inclusion of all patients
undergoing ﬁstula placement is important because approx-
imately one third of all patients have had a prior ﬁstula or
graft, and half or more of those patients have had a
tunneled dialysis catheter. Inclusion of all patients makes
our ﬁndings more applicable to the clinical population of
patients having AVFs placed.This study tested whether preoperative clinical covari-
ates were associated with ﬁstula maturation or long-term
patency. CAD was signiﬁcantly associated with a decreased
risk of long-term ﬁstula failure but not with failure of ﬁstula
maturation. The prevalence of CAD in our cohort (29%)
was similar to that found in the study by Lok et al19
(32%) and a larger study using Centers for Medicare and
Medicaid Services data by Lilly et al20 (24%). Although
Lok et al found that CAD was associated with a signiﬁ-
cantly increased risk of failure of maturation, others have
not reported an association of atherosclerotic heart disease
and ﬁstula maturation.20,21 The association between CAD
and a decreased risk of failure in the long-term patency
model may be secondary to the use of antiplatelet medica-
tions in patients with CAD. Patients with CAD as deﬁned
in this study are more likely to be receiving antiplatelet
therapy to promote patency of cardiac stents or vessels.
The use of antiplatelet medications has been shown to
decrease thrombosis of AVFs in two different meta-ana-
lyses.22,23 A randomized controlled trial of clopidogrel
that was terminated early because of the absence of a treat-
ment effect on ﬁstula suitability for dialysis also showed
that the treatment arm had a signiﬁcantly decreased rate
of ﬁstula thrombosis.15 Although that trial did not address
long-term patency, patients in our study with CAD may
have had better long-term patency because of the use of
antiplatelet medications than did patients without CAD,
who may not have been taking antiplatelet medications.
Patient medication regimens were not reviewed for this
study, but future prospective studies can assess this
hypothesis.
Being on dialysis before ﬁstula placement was associ-
ated with improved long-term patency but not with ﬁstula
maturation. We did not ﬁnd that other demographic and
clinical characteristics were signiﬁcantly related with ﬁstula
maturation or patency. Some clinical and demographic
characteristics (age, sex, BMI, PVD, cardiovascular disease,
or race) have been associated with ﬁstula maturation in
some prior studies but not in others.7,10,12,20,24 Vein diam-
eter has been acknowledged as perhaps the most relevant
and consistent characteristic, which must be considered in
any future models of risk of ﬁstula failure.20,25 In our study,
Table IV. Cox model of long-term patency
Variable b-coefﬁcient HR 95% CI P value
MVD, mm 0.447 0.639 0.485-0.843 .001
Male sex (reference: female) 0.094 0.910 0.535-1.550 .730
Age, years 0.002 0.998 0.980-1.016 .841
Diabetic (reference: not diabetic) 0.296 0.744 0.409-1.353 .332
Preoperative dialysis (reference: no preoperative dialysis) 0.744 2.104 1.115-3.971 .022
African American race (reference: white) 0.205 0.815 0.440-1.509 .515
CAD (reference: no CAD) 0.746 0.474 0.234-0.963 .039
PVD (reference: no PVD) 0.300 0.741 0.218-2.516 .631
CAD, Coronary artery disease; CI, conﬁdence interval; HR, hazard ratio; MVD, minimum vein diameter; PVD, peripheral vascular disease.
Time is months to dialysis; event is ﬁstula failure. Increased MVD was associated with a decreased risk in ﬁstula failure.
Table III. Cox model of ﬁstula maturation
Variable b-coefﬁcient HR 95% CI P value
MVD, mm 0.589 0.555 0.366-0.841 .005
Male sex (reference: female) 0.052 1.053 0.520-2.132 .886
Age, years 0.019 0.981 0.957-1.005 .125
Diabetic (reference: not diabetic) 0.735 0.480 0.206-1.117 .088
Preoperative dialysis (reference: no preoperative dialysis) 0.881 2.412 0.979-5.943 .056
African American race (reference: white) 0.463 0.629 0.281-1.409 .260
CAD (reference: no CAD) 0.815 0.443 0.159-1.235 .120
PVD (reference: no PVD) 0.584 1.794 0.371-8.678 .468
CAD, Coronary artery disease; CI, conﬁdence interval; HR, hazard ratio; MVD, minimum vein diameter; PVD, peripheral vascular disease.
Time is months to dialysis; event is ﬁstula failure. Increased MVD was associated with a decreased risk in failure of maturation of the ﬁstula.
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maturation and long-term patency.
There are several limitations to this study. First, this is a
retrospective review, so the determination of the placement
of the ﬁstula in a particular location was made by clinical
judgment of the operating surgeon. Patients with small
vein diameter or multiple comorbidities may have under-
gone graft placement because of the surgeon’s preference,
and patients with small-diameter veins may have had the
ﬁstula placed at an alternative site according to the sur-
geon’s judgment. This may have introduced a selection
bias in this retrospective cohort. Second, this was a retro-
spective study, so information such as ﬂow rate, Kt/V,
and needle size requirements to determine the adequacy
of the access for dialysis are not available.
Third, there may be considerable day-to-day variability
in vein diameters, depending on the patient’s hydration,
type of anesthesia used, and technique (eg, use of tourni-
quet or not) or different vascular technologists. During
the study period, ultrasound was not routinely performed
intraoperatively. Thus, a single measure on which to base
the choice of operation type and location should be inter-
preted with caution, and certainly repeating the ultrasound
study intraoperatively under anesthesia may provide greater
accuracy. Most important, ultrasound measurements
should not override clinical judgment to proceed with
AVF if the vein was found to be larger intraoperatively
than reported by prior duplex ultrasound or easily disten-
sible. Indeed, this was the practice of the surgeons during
this study period. Whereas many vascular surgeons alsoperform intraoperative ultrasound mapping to conﬁrm
suitable vessels or to mark the surgical site,6 others have
shown that preoperative duplex ultrasound is 98% consis-
tent with intraoperative ﬁndings.7 We think that our ﬁnd-
ings are relevant even in situations in which preoperative
duplex ultrasound alone is performed before anesthesia
administration.
The results of this study do not describe a deﬁnitive
threshold for an MVD that is predictive of ﬁstula matura-
tion or long-term patency, and the analyses were not
intended to do so. As previous risk models for AVF matu-
ration19 did not include vein diameter, and preoperative or
intraoperative duplex ultrasound to assess vein diameter has
become the standard of care for arteriovenous access sur-
gery, we sought to further deﬁne whether vein diameter
is a predictor of maturation or long-term patency indepen-
dent of other common clinical covariates. Results from the
univariate Kaplan-Meier and multivariate Cox regression
models consistently indicate that a reduced vein diameter
is associated with increased risk of an adverse outcome.
Others have suggested a diameter of 4.0 mm as a
threshold for successful ﬁstula maturation, but no deﬁnitive
MVD threshold has been described.10 One interpretation
of our study is that even the majority of AVFs using small
veins (<3 mm) mature and may be successfully used for
dialysis. Further prospective research using area under the
receiver operating curve methods is indicated to statistically
determine clinically relevant and deﬁnitive thresholds for
MVD and the utility of incorporating vein diameter in pre-
dictive risk models of ﬁstula outcomes.
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Patients with a larger vein diameter on preoperative
vein mapping are at lower risk for failure of ﬁstula matura-
tion and have increased long-term AVF patency. Duplex
ultrasound should be used to determine the MVD of the
vein for potential future ﬁstula operations. Physicians can
use the MVD measurement to have a discussion with pa-
tients about the potential success or failure of the ﬁstula.
MVD was the only clinical or demographic factor associ-
ated with both AVF maturation and long-term patency.
MVD is an important preoperative indicator of likely ﬁstula
success in assessing potential AVF sites, and future models
to predict AVF maturation and patency should include vein
diameter.
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